Global Organ Transplant Immunosuppressant Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
Global Organ Transplant Immunosuppressant Drugs Market: Overview
“The global Organ Transplant Immunosuppressant Drugs Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031.”
Organ transplant immunosuppressant drugs are specialized drugs that are administered to ensure the chances of organ rejection after a transplantation procedure has taken place are reduced.
Individuals are at risk of suffering from transplant rejection as the recipient's immune system detects a foreign tissue presence and then goes about destroying it, as a self-preservation reflex. The use of these drugs is vital in helping avoid organ rejection and other damages that may arise due to the transplant. These drugs weaken the immune system, and so, dampen a recipient’s reaction to the foreign organ.
There are basically two types of immunosuppressants, namely - induction immunosuppression and maintenance immunosuppression drugs. The induction immunosuppression is intense, prophylactic therapy used during the transplantation process and, it only lasts for a short span of time. The maintenance immunosuppression drugs, on the contrary, have a longer-lasting impact on the body and are used as part of long-term organ treatment to maximize organ function, mitigate the risk of adverse effects, and minimize the risk of rejection.
Global Organ Transplant Immunosuppressant Drugs Market: Dynamics
An increase in demand for organ transplants and the improvements in drug administration processes are some major factors of market growth. Increasing expenditure on healthcare facilities and infrastructure by various governments are also among the key factors that are expected to drive market growth. Investments made by various manufacturers and companies for the development of novel drugs that can help provide effective treatment is projected to deliver a boost in sales.
However, the high cost of treating organ dysfunctions and conducting an organ transplant may turn out to be major factors that may restrain the growth of the market. In addition, inadequate or insufficient availability of organ donors is among some of the other restraining factors affecting the global organ transplant immunosuppressant drugs market.
Global Organ Transplant Immunosuppressant Drugs Market: Regional Analysis
North America is projected to account for a majority of the market’s revenue share over the forecast period due to a rise in healthcare expenditures, the establishment of R&D infrastructure, the introduction of healthcare reimbursement policies and an increase in demand for organ transplants. The market in Europe is expected to account for the second-highest revenue share throughout the forecast period.
The Asia Pacific market is projected to index a high Compounded Annual Growth Rate (CAGR). Increasing revenue generation from calcineurin inhibitors to mTOR inhibitors in this region is one of the key factors that will spike the market’s growth. The growing adoption of reimbursement policies and increasing investments by respective governments and manufacturers in the healthcare sector are among other major factors for the growth of the market in this region.
Global Organ Transplant Immunosuppressant Drugs Segmentation:
- Calcineurin Inhibitors
- Antiproliferative Agents
- mTOR Inhibitor
By Transplant Type
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Astellas Pharma Inc.
- Sanofi Genzyme
- Accord Healthcare Ltd.
- Novartis AG
- Mylan Laboratories, Inc.
- Reddy’s Laboratories Ltd.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Veloxis Pharmaceuticals A/S
- Bristol-Myers Squibb Company
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!